Pre-pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa: systematic review and meta-analysis

Short title: Systematic review: pre-pandemic SARS-CoV-2 immunity

John P.A. Ioannidis, MD, DSc[1], Despina G. Contopoulos-Ioannidis, MD[2]

1 Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Sciences, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford CA, USA

2 Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Correspondence: John P.A. Ioannidis, MD, DSc, 1265 Welch Rd, SPRC, Medical School Office Building X306, Stanford, CA 94305, USA E-mail: jioannid@stanford.edu .

3499 words; 3 tables; 1 figure; Supplement Appendix including Supplementary References, 5 supplementary tables, 1 supplementary figure, and Supplementary Excluded References; abstract: 200 words

PROTOCOL REGISTRATION NUMBER OSF f5g76

ABSTRACT (200 words)

Objective: To assess the evidence on the presence of antibodies cross-reactive with SARS-CoV-2 antigens in pre-pandemic samples from African populations.

Methods: We performed a systematic review and meta-analysis of studies evaluating pre-pandemic African samples using pre-set assay-specific thresholds for SARS-CoV-2 seropositivity.

Results: 26 articles with 156 datasets were eligible, including 3,437 positives among 29,923 measurements (11.5%) with large between-dataset heterogeneity. Positivity was similar for anti-N (14%) and anti-S antibodies (11%), higher for anti-S1 (23%) and lower for anti-RBD antibodies (7%). Positivity was similar, on average, for IgM and IgG. Positivity was seen prominently in countries where malaria transmission occurs throughout and in datasets enriched in malaria cases (14%, 95% CI, 12-15% versus 2%, 95% CI 1-2% in other datasets). Substantial SARS-CoV-2 reactivity was seen in high malaria burden with or without high dengue burden (14% and 12%, respectively), and not without high malaria burden (2% and 0%, respectively). Lower SARS-CoV-2 cross-reactivity was seen in countries and cohorts of high HIV seroprevalence. More sparse individual-level data showed associations of higher SARS-CoV-2 cross-reactivity with *Plasmodium* parasitemia and lower SARS-CoV-2 cross-reactivity with HIV seropositivity.

Conclusions: Pre-pandemic samples from Africa show high levels of anti-SARS-CoV-2 seropositivity. Levels of cross-reactivity tracks especially with malaria prevalence.

47   **Keywords:** COVID-19, SARS-CoV-2, malaria, cross-reactivity, pre-pandemic, seroprevalence.

INTRODUCTION

Recorded COVID-19 deaths in Africa during the pandemic were few compared with

other continents. Diverse explanations have been proposed [1], ranging from favorable

population features (very young, low obesity rates) to undercounted deaths due to limited testing

[2]. A most tantalizing hypothesis has invoked pre-existing immunity to SARS-CoV-2. Impetus

for this hypothesis has been provided by studies assessing cross-reactive humoral immunity to

SARS-CoV-2 in pre-pandemic African samples (Supplementary References [S1-S26]). This

cross-reactivity has typically been absent in highly developed countries. Cross-reactivity to

endemic coronaviruses is one possibility (e.g., see Supplementary References [S10, S25] for

humoral and T-cell cross-reactivity), but it may not suffice to explain this phenomenon, and

endemic coronaviruses are ubiquitously distributed across all continents. There have been

speculations whether cross-reactive antibodies reflect exposure to other infectious pathogens

widespread in Africa like *Plasmodium*, dengue and HIV.

African studies on cross-reactivity have used diverse sources of pre-pandemic samples in

various countries. They have also used different assays for various antibody types and SARS-

CoV-2 antigenic targets. There are conflicting hints on whether cross-reactivity may pertain

mostly to specific antibody types and targets. Some studies (see Supplementary References [S2,

S7, S8, S9, S10, S14, S15, S23, S25, S26) have also explored different correlations between the

presence of anti-SARS-CoV-2 cross-reactivity and markers of various other pathogens. A

systematic examination may offer some more concrete insights. Important questions to answer

are: how frequently are SARS-CoV-2 cross-reactive antibodies detected in pre-pandemic African

samples, how much heterogeneity exists on their prevalence, and whether heterogeneity may be

explained by antibody types and targets, each country's endemicity for *Plasmodium* and dengue,

and HIV infection rates. This systematic review and meta-analysis addressed these questions.

METHODS

The systematic review follows the PRISMA 2020 statement. The study protocol was

registered on 9/13/2022 with registration number OSF f5g76 (https://osf.io/f5g76/).

Eligible studies

Eligible studies were those that evaluated samples collected in African countries before

December 2019, i.e. in the pre-pandemic period, for humoral responses to SARS-CoV-2 in blood

(plasma or serum). Any type of antibody and any type of assay thereof was eligible. Studies were

eligible if they used pre-set assay-specific thresholds of antibody titers for claiming positive

results. Studies that measured antibodies in other body fluids (e.g., milk) were excluded. Studies

that calibrated the assay threshold so as to make it appropriate for use in African populations by

setting the specificity at a desired level were excluded; however, if these studies presented also

specificity results according to an original pre-set threshold (based on previous work on other,

non-African populations), the estimates of specificity based on the pre-set threshold were

eligible. Similarly, studies that used assays that were previously calibrated so as to have a

desirable level of specificity in African samples were excluded. Furthermore, studies that

considered only pre-pandemic samples that were already screened to be negative for anti-SARS-

CoV-2 antibodies based on some other SARS-CoV-2 antibody assay were excluded. For studies

that included both African and other continent samples from the pre-pandemic era, only the

former were eligible, and data were thus considered only if the African set could be separated.

We did not consider functional (e.g. neutralizing antibody assays) or cellular immunity assays.

Search strategies

PubMed was searched (last update May 11, 2023) with the following search string:

(Nigeria OR Ethiopia OR Egypt OR Congo OR Tanzania OR South Africa OR Kenya OR

Uganda OR Sudan OR Algeria OR Morocco OR Angola OR Mozambique OR Ghana OR

Madagascar OR Cameroon OR Cote d'Ivoire OR Niger OR Burkina Faso OR Mali OR Malawi

OR Zambia OR Senegal OR Chad OR Somalia OR Zimbabwe OR Guinea OR Rwanda OR

Benin OR Burundi OR Tunisia OR South Sudan OR Togo OR Sierra Leone OR Libya OR

Liberia OR Central African Republic OR Mauritania OR Eritrea OR Namibia OR Gambia OR

Botswana OR Gabon OR Lesotho OR Guinea-Bissau OR Africa OR African) AND (pre-

pandemic OR prepandemic OR cross-reactiv* OR seroprevalence OR negative samples OR

negative controls OR (specificity AND test) OR (specificity AND antibod*)) AND (COVID-19

OR SARS-CoV-2). We also searched the reference lists of the retrieved eligible papers and

searched in Google Scholar the articles that cite the retrieved eligible papers in order to identify

any additional relevant eligible papers.

Data extraction

From each eligible paper, we extracted the following information: first author,

publication venue, African county(ies) from which pre-pandemic samples were obtained, sample

size (per country and per cohort, if many countries/cohorts were assessed), provenance of the

samples and any information about the sampling process, time periods when they were collected,

age information; type of SARS-COV-2 assays and of antibodies measured, including

manufacturer or laboratory of provenance, type of antibody (IgG, IgM, IgA, combinations, all

antibodies) and antigenic targets (spike S, S1 subunit, S2 subunit, nucleocapsid N, receptor

binding domain RBD, receptor binding motif RBM, other); number and percentage of positive

samples for each antibody and antigenic target assessed among total assessed; any borderline

readings; any additional information on measurements of indicators of other infectious diseases

(*Plasmodium* parasitemia, *Plasmodium* antigens, HIV positivity status, dengue, other) with the

potential to generate 2x2 tables for SARS-CoV-2 antibodies against these indicators; and any

additional information on relationships between SARS-CoV-2 antibodies and other factors

assessed by the authors.

Data extraction was performed in duplicate by two independent assessors who then

compared notes and solved discrepancies with discussion.

123 Risk of bias assessment

124 Eligible articles were assessed using the Joanna Briggs risk of bias tool for prevalence

125 studies that includes 9 assessment items [3]. Assessment was done by one assessor.

126 Meta-analysis

Available data on percentage of positive samples with different assays and antigenic

targets were combined with meta-analysis using a random effects model [4]. Heterogeneity was

assessed with the chi-square-based Q test and with the I^2 statistic [5]. Borderline readings were

considered negative (as also done by the original individual study authors).

Subgroup analyses were performed according to type of antibody (IgG, IgM, IgA,

combinations, all antibodies). Moreover, when different types of antibody (e.g. IgG and IgM)

had been assessed with the same assay platform in the same samples, the matched McNemar

odds ratio was calculated.

We also performed subgroup analyses according to country of origin of the samples,

classifying countries according to endemicity/burden for malaria, dengue, and rates of HIV

infection. For malaria, we used the CDC map of malaria distribution [6] separating countries

where malaria transmission occurs throughout versus those where no transmission occurs or

transmission occurs only in some places. For dengue, we used the Global Consensus 2013 map

[7] separating countries where dengue is present or likely from countries where dengue in

uncertain, unlikely or absent. For HIV, we considered the eight countries with highest HIV

positivity rates (>10% according to CIA fact book and UNAIDS AIDS info [8], i.e. Botswana,

Lesotho, Mozambique, Namibia, South Africa, Eswatini, Zambia, and Zimbabwe) versus others.

Studies where sampling explicitly aimed to recruit participants based on or heavily enriched in

Plasmodium, dengue, or HIV infections were considered in the groups with high burden, even if

they come from countries without high burden.

When many studies presented individual-level data to construct 2x2 tables for the

association between anti-SARS-CoV-2 antibodies and other infectious disease markers, random

effects meta-analyses of the calculated odds ratios were also performed. For the association

between *Plasmodium* parasitemia and SARS-CoV-2 antibodies, we also used the Fisher method

to combine p-values across studies that used different association metrics.

Meta-analyses were conducted in STATA SE 15. P-values were considered statistically

significant for P<0.005 and suggestive for values between 0.005 and 0.05 [9].

RESULTS

Eligible studies

We screened 2,284 published items (Figure 1) of which 47 were screened in full text. 24

were excluded and 21 were eligible, while 3 more eligible studies (one article, one thesis and one

preprint) were retrieved from cited/citation searches for a total of 26 eligible studies

(Supplementary References [S1-26]). Studies screened in-depth and excluded are shown in

Supplementary Excluded References along with reasons for exclusion. Supplementary Table 1

shows the results of the risk of bias assessment.

With one exception participants came from Sub-Saharan Africa (Table 1). Dataset sample

sizes ranged from 19 to 1,077 (sum=29,923). There was also wide variation in the settings of

sample collection and eligibility criteria. Six studies included independent cohorts from more

than one country and two studies included different cohorts from the same country. Most

samples were selected between 2016 and 2019, but 10 cohorts had earlier samples (earliest,

1999). Most cohorts had collected samples from both children and adults, but several included

only adults and 2 included only children (Table 1).

There was a large variety of assays used, but most studies used assays of IgG (Table 2).

Most studies assessed antibodies against both spike and nucleocapsid, but antigenic targets

varied across studies (Table 2). In-depth assessments for associations with indicators of

infectious pathogens were sparse.

Presence of SARS-CoV-2 antibodies

Overall, 156 datasets (Supplementary Table 2) among pre-pandemic samples were

available for analysis with crude total of 3,437 positives among 29,923 measurements (11.7%,

95% CI, 11.1-11.9%). When all 156 datasets were considered in meta-analysis, there was large

between-dataset heterogeneity (p<0.001, I^2=96.5%) with several studies finding 0% positivity

and some others exceeding 80% (summary random effects 11%, 95% CI, 10-12%).

Meta-analysis of positivity per antigenic target and antibody type

As shown in Table 3, summary positivity was similar for anti-N (14%, 95% CI, 11-16%)

and anti-S (11%, 95% CI, 10-12%) antibodies. However, subtypes within spike had different

profiles and summary positivity was higher for anti-S1 (23%, 95% CI, 18-27%) and lower for

anti-RBD antibodies (7%, 95% CI, 5-8%). Lowest positivity was seen for antibodies using both

N and S (or subtype) targets (5%, 95% CI, 3-7%). Positivity was overall similar for IgM

(summary 13%) and IgG (summary 11%) antibodies, but prominence of IgM versus IgG signals

varied greatly across datasets. There was very large between-dataset heterogeneity in all

summary estimates (p<0.001), so they should be seen with great caution.

Paired comparisons of antibody types

In 18 datasets, both IgG and IgM had been measured with the same type of assays and

antigenic target on the same samples. For 16/18, data on paired measurements in each sample

were available (Supplementary Table 3, in another 2 small datasets had no sufficient data to

calculate paired odds ratios). The results were very heterogeneous making their synthesis

precarious: in 7 datasets 95% confidence intervals of the paired odds ratio excluded the null, but

in 4 datasets, samples positive only by IgM outnumbered samples positive only by IgG, while

the opposite situation was seen for 3 datasets.

Subgroup analyses for malaria, dengue, and HIV (Table 3)

Anti-SARS-CoV-2 positivity was very different according to malaria status. It was seen

prominently in countries where malaria transmission occurs throughout and in datasets enriched

in malaria cases (summary estimate 14%, 95% CI, 12-15%), but was almost absent in other

datasets (summary estimate 2%, 95% CI, 1-2%). There was still very large between-study

heterogeneity in the former group, and less heterogeneity in the latter. Among the 30 datasets in

the latter group, positivity was always 0% or very low (=<8%) except for one dataset from

Tanzania which is a country where malaria transmission does occur throughout in altitudes

below 1800 meters.

A higher proportion of anti-SARS-CoV-2 positivity was seen in high dengue burden

datasets than others (summary estimates 12% versus 9%), but large between-dataset

heterogeneity existed within each group (p<0.001).

When data were analyzed in 4 subgroups according to both malaria and dengue burden

(Supplementary Figure), seropositivity was similar in settings with high malaria burden

regardless of whether they had high or low dengue burden (14% [95% CI, 13-16%] and 12%

[95% CI, 9-14%], respectively). Conversely, there was low or no seropositivity in settings with

low malaria burden, regardless of whether they had high or low dengue burden (2% [95% CI, 1-

3%] and 0% [95% CI, 0-1%], respectively).

An inverse association was seen with HIV infection, with lower proportions of anti-

SARS-CoV-2 antibody positivity in countries with high HIV transmission or datasets with >10%

of the sample being HIV-positive than in datasets with lower HIV rates (summary positivity 6%

versus 13%). There was large between-dataset heterogeneity (p<0.001) within each group.

Association with Plasmodium parasitemia (data at sample level)

One study (supplementary reference [S9]) provided 2x2 tabular data on positivity with 4

different anti-SARS-CoV-2 IgG assays in subgroups defined by the presence of *Plasmodium*

parasitemia. Combining the 4 evaluations, summary odds ratio was 1.84 (95% CI, 0.90-3.78,

I^2=29.2%). 15 evaluations from 3 studies (supplementary references [S2, S8, S9]) presented

various examinations of the association between *Plasmodium* parasitemia and anti-SARS-CoV-2

cross-reactivity using diverse metrics: combining the 15 p-values yielded p=0.009 for the overall

association (Supplementary Table 4).

Association with HIV seropositivity (data at sample level)

Four studies (supplementary references [S7, S10, S25, S26]) included data from 8

datasets where SARS-CoV-2 cross-reactivity was given per HIV serostatus (Supplementary

Table 5). Summary odds ratio for the association between SARS-CoV-2 antibodies and HIV

seropositivity was 0.69 (0.49-0.96, I^2=0%).

Data were limited or not presented in sufficient detail for formal meta-analysis for other

infectious disease indicators.

DISCUSSION

The present meta-analysis includes data from 26 studies with 156 datasets and

approximately 30,000 measurements of anti-SARS-CoV-2 antibodies in pre-pandemic samples

from Africa. On average, approximately 1 of 9 samples tested positive for anti-SARS-CoV-2

antibodies, but there was extensive heterogeneity across studies and datasets. Stark differences

were seen according to malaria burden. Anti-SARS-CoV-2 cross-reactivity was seen almost

entirely in samples from areas with malaria transmission throughout and/or enriched in malaria

cases. A more modest association was seen for dengue. However, malaria and dengue

endemicity largely overlap, and samples coming from high dengue but low malaria burden

settings had negligible anti-SARS-CoV-2 cross-reactivity. Finally, HIV was associated with

lower frequency of anti-SARS-CoV-2 antibodies. These associations with pathogen burden are

based on inferences about the frequency of these infections at group/country-level rather than

individual samples; therefore they should be seen with great caution for potential ecological

fallacies. Nevertheless, also in the more sparse data on individual samples, *Plasmodium*

parasitemia was associated with higher SARS-CoV-2 cross-reactivity and HIV seropositivity

was associated with lower SARS-CoV-2 cross-reactivity.

The composite picture is consistent with the possibility that the observed pre-pandemic

seropositivity to SARS-CoV-2 in Africa may partly reflect cross-reactive response to malaria.

Lapidus et al. suggest that this immune response is more common and more intense in acute and

recent malaria [10], may reflect antibodies targeting sialic acid moieties on the S1 fragment, and

cross-reactivity is effectively reduced when sialic acid is cleaved from the assay target [10]. The

large between-dataset heterogeneity among studies with high malaria burden may reflect both

antibody assay variability and diversity in the magnitude of the malaria burden: some datasets

included exclusively acute malaria, others were heavily enriched in malaria cases, and others

simply came from areas with substantial malaria burden. Most areas in Africa with high dengue

burden have also high malaria burden. Datasets from settings with high dengue but low malaria

showed negligible anti-SARS-CoV-2 positivity. Prospective studies with pandemic and post-

pandemic samples should further evaluate the relationship between malaria and SARS-CoV-2

seropositivity.

Anti-SARS-CoV-2 humoral cross-reactivity in pre-pandemic samples has generally not

been observed in European and USA studies. Data from countries outside Africa also suggest

that malaria rather than dengue has a strong association with SARS-CoV-2 cross-reactive

antibodies. Manning et al. [11] found 14% cross-reactive positivity among 528 malaria patients

from Cambodia. More studies on individual samples with documented malaria are needed from

non-African areas. Data for dengue are mixed. One study in Taiwan [12] found higher optical

density anti-S1 RBD activity in archival dengue samples than controls, but optical density values

were still low. Another study [13] found some IgM and IgA rather IgG false-positivity for

SARS-CoV-2 in dengue febrile illness in Thailand, but false-positivity tended to be even more

frequent for non-dengue febrile illness (including apparently malaria). In samples from Puerto

Rico and USA [14], dengue did not induce cross-reactive antibodies to SARS-CoV-2; the same

was true in dengue samples from Indonesia [15], Colombia [16] and travel clinics [17].

Conversely, another study [18] found 22% cross-reactivity in samples from an Israel center

(unspecified country of provenance); however, it is unknown whether any positive samples could

be from patients with malaria history. SARS-CoV-2 infection produces cross-reactive antibody

activity to dengue in some [14,15,18] but not all [13] studies. Anti-SARS-CoV-2 antibodies may

also have a protective role for dengue [11]. Interestingly, reported dengue cases and deaths

declined in 2020-2022 after a peak in 2019 [19], but this may also reflect the impact of

containment measures on communicable diseases in general. In-silico analysis shows possible

similarities between SARS-CoV-2 epitopes in the HR2 domain of spike and the dengue envelope

protein [18], but evidence is again stronger for malaria, where cross-reactive antibodies

specifically recognized the sialic acid moiety on N-linked glycans of spike [10].

The clinical and public health importance of pre-existing humoral cross-reactivity

remains a tantalizing question. Evidence is mixed. Some studies have suggested that the detected

antibodies in pre-pandemic samples test negative in neutralization assays [10,20]. Conversely, Li

et al. [21] found neutralizing responses in some pre-pandemic samples; neutralizing and binding

activities did not correlate. Stronger evidence for neutralizing activity was obtained by

Nyagwange et al [22]. who analyzed pre-pandemic samples from coastal Kenya and found

neutralization for pseudotyped reference SARS-CoV-2 with a mean infective dose 50 of 1:251,

which is still within predicted protection levels. In the same study, the pre-pandemic naso-

oropharyngeal fluid samples also neutralized pseudo-SARS-CoV-2 at a mean infective dose 50

of 1:5.9.

These cross-reactive antibodies may be a marker of a much broader immune response

with both humoral and cellular features. Pre-existing T-cell immunity and its potential role in

ameliorating clinical course in SARS-CoV-2 infection is another debated issue [23]. It would be

useful to assess pre-pandemic samples with anti-SARS-CoV-2 antibodies for a broad spectrum

of immune functionalities. Non-humoral immunity elements appear even more frequent than the

detected humoral immunity, since humoral immunity tends to wane relatively rapidly [24].

Cross-reactive CD4+ and CD8+ T-cell responses to SARS-CoV-2 were documented in 90% of

pre-pandemic samples from Uganda [25], but only 10-50% in pre-pandemic samples from the

USA or Europe [26-28]. Cross-reactive T-cell responses may derive from both homologous

pathogens (other coronaviruses, including the 4 globally-distributed coronaviruses or other

coronaviruses with country distribution largely overlapping with malaria burden [20]) and non-

homologous ones (e.g. CMV) [29].

The geographical pattern of the documented impact of COVID-19 in Africa is

intriguingly well-aligned with the geographical pattern of detected pre-pandemic humoral cross-

reactivity. Recorded COVID-19 deaths have been far higher in South Africa (high HIV,

relatively low malaria burden) and in northern African countries (low malaria burden) than in

other countries in sub-Saharan Africa (high malaria burden). These areas are unlikely to have

differed in prior exposure to the 4 well-known endemic coronaviruses. However, differences in

other environmental conditions or in the extent of contact with wildlife carrying other

coronaviruses are an alternative possibility [20]. Differences in the extent of under-

ascertainment of COVID-19 deaths, demographic and lifestyle differences (older populations in

northern Africa, high levels of obesity in South Africa) may also partly underlie these

differences. However, a contribution of pre-existing immunity remains also an additional

possibility. Pre-existing immunity may have contributed also to relatively low fatalities in East

Asia. Many areas in East Asia also have substantial malaria burden. Conversely, recent dengue

outbreaks did not seem to protect from COVID-19 fatalities; the highest dengue burden in 2019

was seen in Brazil, a country that suffered high COVID-19 fatalities.

Our work has limitations. First, the examined studies mostly used convenient samples

available from pre-pandemic efforts not tailored specifically to answer questions posed by the

pandemic. For many samples, information about their provenance and features was limited.

Second, several analyses have ecological designs, e.g. when countries were assigned to high or

low burden groups for specific pathogens. The observed associations may not necessarily hold

true also in analyses profiling prior infection in single individual samples. The potential for

ecological fallacy plus the high between-dataset heterogeneity should add extra caution to the

interpretation of the results of the presented meta-analyses. Nevertheless, the more limited

individual sample-level data available also agree with the main findings regarding malaria [30]

and HIV. Third, some analyses include datasets which represent the same samples tested with

different assays, therefore they are not entirely independent. However, the major differences

observed (e.g. with malaria) remain strong even if only one dataset is selected per study/cohort

(not shown). Fourth, it is uncertain if due to publication bias more studies that found no

seropositivity in pre-pandemic African samples may have remained unpublished compared with

studies that found high positivity. Fifth, the assays used were very diverse and the technical

competence of their performance by different teams cannot be validated independently. This may

explain also part of the observed large between-dataset heterogeneity. However, errors would

tend to weaken observed associations, if anything, through non-differential mis-classification.

Acknowledging these caveats, our meta-analysis provides strong evidence for pre-

pandemic cross-reactive humoral immunity to SARS-CoV-2 in Africa, closing tracking with

malaria. Further studies of broader immunological profiles involved and of the public health

implications are necessary.

Contributors

347   Both authors conceived the original idea, wrote the protocol, extracted data, run and

348   interpreted analyses, wrote and revised the paper and approved the final version.

349   **Funding**

350   None

351   **Declaration of interests**

352   No conflicts of interest.

353   **Data sharing statement**

354   All data are in the manuscript and its supplements

355   **Ethical approval**

356   Not applicable

REFERENCES

[1] Adams J, MacKenzie MJ, Amegah AK, Ezeh A, Gadanya MA, Omigbodun A, et al. The

conundrum of low COVID-19 mortality burden in sub-Saharan Africa: myth or reality?. Glob

Health Sci Pract 2021;9(3):433-443.

[2] Ioannidis JPA. Over- and under-estimation of COVID-19 deaths. Eur J Epidemiol

2021;36(6):581-588.

[3] Munn Z, Moola S, Riitano D, Lisy K. The development of a critical appraisal tool for use in

systematic reviews addressing questions of prevalence. Int J Heal Policy Manag 2014;3(3):123–

8.

[4] Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern

Med 1997;127(9):820-6.

[5] Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin

Pract 2008;14(5):951-7.

[6] CDC. Malaria distribution, in: https://www.cdc.gov/malaria/about/distribution.html, last

accessed September 13, 2022.

[7] Dengue Global Consensus 2013 map, in https://www.healthmap.org/dengue/en/, last

accessed September 13, 2022.

[8] AIDS adult prevalence, in

https://en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate, last

accessed September 13, 2022.

[9] Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers EJ, Berk R, et al.

Redefine statistical significance. Nat Hum Behav 2018;2(1):6-10.

[10] Lapidus S, Liu F, Casanovas-Massana A, Dai Y, Huck JD, Lucas C, et al. Plasmodium

infection is associated with cross-reactive antibodies to carbohydrate epitopes on the SARS-

CoV-2 spike protein. Sci Rep 2022;12(1):22175.

[11] Manning J, Zaidi I, Lon C, Rosas LA, Park JK, Ponce A, et al. SARS-CoV-2 cross-

reactivity in prepandemic serum from rural malaria-infected persons, Cambodia. Emerg Infect

Dis 2022;28:440–4.

[12] Cheng YL, Chao CH, Lai YC, Hsieh KH, Wang JR, Wan SW, et al. Antibodies against the

SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Front

Immunol 2022;13:941923.

[13] Luvira V, Leaungwutiwong P, Thipporrnchai N, Thawornkuno C, Chatchen S,

Chancharoenthana W, et al. False positivity of anti-SARS-CoV-2 antibodies in patients with

acute tropical diseases in Thailand. Trop Med Infect Dis 2022;7(7):132.

[14] Munoz-Jordan J, Cardona J, Beltrán M, Colón C, Schiffer J, Stewart-Clark E, et al.

Evaluation of serologic cross-reactivity between dengue virus and SARS-CoV-2 in patients with

acute febrile illness - United States and Puerto Rico, April 2020-March 2021. MMWR Morb

Mortal Wkly Rep 2022;71(10):375-377.

[15] Santoso MS, Masyeni S, Haryanto S, Yohan B, Hibberd ML, Sasmono RT. Assessment of

dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia. Virol J

2021;18(1):54.

[16] Faccini-Martínez ÁA, Rivero R, Garay E, García A, Mattar S, Botero Y, et al. Serological

cross-reactivity using a SARS-CoV-2 ELISA test in acute Zika virus infection, Colombia. Int J

Infect Dis. 2020;101:191-193.

[17] Spinicci M, Bartoloni A, Mantella A, Zammarchi L, Rossolini GM, Antonelli A. Low risk

of serological cross-reactivity between dengue and COVID-19. Mem Inst Oswaldo Cruz.

2020;115:e200225.

[18] Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential

antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-

2) and dengue viruses. Clin Infect Dis 2021;73(7):e2444-e2449.

[19] WHO. Dengue and severe dengue, update Jan 10, 2022.

[20] Souris M, Tshilolo L, Parzy D, Lobaloba Ingoba L, Ntoumi F, Kamgaing R, et al. Pre-

Pandemic cross-reactive immunity against SARS-CoV-2 among Central and West African

populations. Viruses 2022;14(10):2259.

[21] Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Swafford I, et al. Coronavirus

antibody responses before COVID-19 pandemic, Africa and Thailand. Emerg Infect Dis

2022;28(11):2214-2225.

[22] Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, et al. Serum

immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples

collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro. Int J Infect Dis 2023;127:11-16.

[23] Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-

specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature

2020;584(7821):457-462.

[24] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al.

Protection and waning of natural and hybrid immunity to SARS-CoV-2. N Engl J Med

2022;386(23):2201-2212.

[25] Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al.

High proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and CD8+

T-cell responses. medRxiv [Preprint] 2023 Jan 20:2023.01.16.23284626. doi:

10.1101/2023.01.16.23284626.

[26] Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-

reactive SARS-CoV-2 T cell epitopes in 284 unexposed humans. Science 2020;370(6512).

[27] Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive

T cells in healthy donors and patients with COVID-19. Nature 2020;587(7833):270–274.

[28] Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of

T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed

individuals. Cell 2020; 181(7):1489-1501.e15

[29] Pothast CR, Dijkland RC, Thaler M, Hagedoorn RS, Kester MGD, Wouters AK, et al.

SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive

CMV-specific T cells. Elife 2022;11:e82050.

[30] Benabdessalem C, Hamouda WB, Marzouki S, Faye R, Mbow AA, Diouf B, et al.

Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in

various African endemic settings. Diagn Microbiol Infect Dis 2023;105(4):115903.

FIGURE LEGEND

Figure 1: Flow diagram for searches and selected eligible studies

446 **Table 1. Characteristics of eligible studies**

Author	Country	Sample size	Provenance of the samples and sampling process	Time period of sample collection	Age in years (median)
Pedersen	Gabon	146	Unclear	Oct 2019	18-50
	Senegal	150	Unclear	Jan 2017- May 2018	65% <18
Borrega	Sierra Leone	120	Lassa and Ebola survivors and their contacts	Sept 2016- April 2019	8-60 (31)
Tso	Tanzania	105	Blood donors, 6.7% HIV-positive	Mar 2019- May 2019	≥18
	Zambia	99	Enriched in HIV-positive (43.4%)	2017- early 2019	≥18
Emmerich	Magadascar	167	Pregnant women	2010	20-30 (23)
	Ghana	150	Children	2014-2015	3-7 (6)
	Ghana	133	Teens and adults	1999	16-45 (22)
	Nigeria	150	Adults	2018	30-58 (41)
Yadouleton	Benin	60	Acute febrile illness, tested for hemorrhagic fever surveillance	Oct 2019 – Nov 2019	12-65 (28)
Nzoghe	Gabon	135	Healthy healthcare worker volunteers	2014	14-80 (38)

Woodford	Mali	312	Urban healthy adults	Jan 2017	≥18
			Rural healthy adults	May 2019	≥18
			Rural women of childbearing age	May 2019	≥18
			Rural all ages	May 2018	All ages
Baker	Uganda	1077	Rakai Community Cohort Study (543 febrile within one month, 534 non-febrile matched for age and gender)	2011-2013	18-54 (30)
Souris	DR Congo	190	Healthy subjects (hospital staff and volunteers) and young sickle-cell disease patients	2019	Any age
	DR Congo	384	Biobank from Plasmodium study in Kinshasa	2014 – 2015	Any age
	Cameroon	383	Continual health monitoring project for HIV patients	Jun 2018 – Jun 2019	Any age
	R Congo	536	Research samples from two districts (Brazaville, Bomassa)	2016, 2019	Any age
	Senegal	162	Biobank samples	2018, 2019	Any age

Ige	Nigeria	100	50 HBV-positive (S-antigen) and 50 HIV-positive	Before Oct 2019	(35)
Traore	Mali	283	Malaria survey in Dangassa village	2019	Unclear
Ingoba	R Congo	82	Bomassa village	Jun- Jul 2019	Unclear
Diagne	Senegal	272	Biobank	Before Sept 2019	Unclear
Yansouni	Senegal	100	Clinical suspects for malaria	Before Jul 2019	Unclear
Iriemenam	Nigeria 1	100	Pre-pandemic samples of hepatitis B (n=50) or HIV (n=50) positive patients	Before Oct 2019	(35)
	Nigeria 2	200	Nigeria HIV/AIDS Indicator and Impact Survey	2018	0-60 (32)
Steinhardt	Nigeria	213	Nigeria HIV/AIDS Indicator and Impact Survey	2018	0-60
Gelanew	Ethiopia	365	Pre-pandemic sera	2012-2018	Unclear
Gebrecherkos	Ethiopia	50	Pre-pandemic samples from patients with other infections	2017	Unclear
Mboumba Bouassa	Central African Republic	100	National center of sexually transmitted diseases in Bangui, 54 HIV-	2000-2011	(31 mean)

			seropositive, 5 HCV-positive, 35 HBsAg-positive		
Gdoura	Tunisia	119	Pre-pandemic samples	Before 2019	Unclear
Vanroye	Diverse African	195[a]	Travelers from Africa with malaria or schistosomiasis	2010-2018	8-61 (~40)
Lapidus	Cameroon	19	Malaria patients	Jul-Nov 2018	2-64 (26 mean)
	Senegal 1	120	Malaria patients	Jul 2019	1-74 (22 mean)
	Senegal 2	67	Malaria patients	2015-2017	5-16 (11 mean)
	Burkina Faso 1	88	Malaria patients	Jul-Aug 2017	0-4 (3 mean)
	Burkina Faso 2	25	Malaria patients	Oct 2016-Feb 2017	21-43 (33)
	Ghana	45	Malaria patients	Jul 2007-June 2010	3-70 (15)
Naidoo	South Africa	316	Pre-pandemic virology serology residual samples	Before November 2019	Unclear
Li	Nigeria	361	RV466/IWARG (febrile illness study)	2014-2019	18-78 (34)
	Uganda	399	RV329/AFRICOS (mostly chronic HIV infection)	2014-2016	20-70 (40)

	Tanzania	234	RV329/AFRICOS (mostly chronic HIV infection)	2014-2016	19-74 (39)
	Kenya	653	RV329/AFRICOS (mostly chronic HIV infection)	2014-2017	19-77 (40)
Nantambi	Uganda	110	Specimens collected for optimization of immunological assays, 68% HIV-positive	2009-1015	Unclear
Aissatou	Cameroon	288	Biobank samples from Centre region of Cameroon, 56% HIV-positive	2017-1018	0=>60 (25)

447   [a]Includes 9 samples from Asia and 19 of unknown country origin; besides the n=195, the study

448   has 25 patients with dengue, but few are from Africa, so only the malaria and schistosomiasis

449   cases are considered here

452 **Table 2. Immunological assays performed in the eligible studies and other pathogen**

453 **indicators assessed**

Author	Antibody assays used	Antigenic targets	Other pathogen indicators assessed
Pedersen	ELISA	S, N	
Borrega	reSARS, cutoffs defined by USA samples	N, RBD, S2	
Tso	Immunofluorescence assay, with USA control samples	N, S	HIV
Emmerich	Euroimmun, EDI, Mikrogen recomWell	S1 IgG (Euroimmun), N IgG (Euroimmun), N IgG (EDI), N IgG (Mikrogen)	*Plasmodium* parasitemia
Yadouleton	Euroimmun, INBIOS	S IgG (Euroimmun), S1 IgA (Euroimmun), S1 IgG (INBIOS), N IgG (Euroimmun)	
Nzoghe	Elecsys Roche	N all subclasses	Multiple infectious indicators assessed but presented only for SARS-C0V-2 antibody-positive samples

Woodford	Previously developed at NIH with USA samples	S, N, RBD	*Plasmodium* antigens
Baker	CoronaCHEK	Spike RBD IgG or IgM	HIV
Souris	INNOBIOCHIPS ELISA, calibrated on other human coronaviruses	S1, S2, S1-RBD, S1-NTD, N	
Ige	Euroimmun, Mologic, Abbott Architect	S1 IgG (Euroimmun), N IgG (Euroimmun), S2 or N IgG (Mologic), N IgG (Abbott)	
Traore	ELISA	S IgG, RBD IgG, RBM IgG	*Plasmodium* parasitemia, *Plasmodium* smear
Ingoba	Virotech, according to kit manufacturer	N IgG (also IgM but no data given)	
Diagne	Omega, ID-screen	N or S2 IgG (Omega), N IgG (ID-screen)	*Plasmodium* and other pathogen antibodies
Yansouni	Abbott Architect, Rapid diagnostic test (RDT)	N IgG (Abbott), N IgM (RDT), N IgG (RDT)	
Iriemenam	Tetracore, SARS2MBA, xMAP, RightSign	RBD IgG, N IgG, RBD-N hubrid IgG (Tetracore); S IgG, RBD541 IgG,	

		RBD591 IgG, N IgG (SARS2MBA); N IgG, RBD IgG, S1 IgG (xMAP); IgG/IgM (RightSign)	
Steinhardt	Euroimmun, Abbott Architect	N IgG (Euroimmun), N IgG (Abbott)	*Plasmodium* antibodies, *Plasmodium* antigens, antibodies for filariasis, oncocherciasis, syphilis/yaws, cystocercosis, taeniasis
Gelanew	ELISA	RBD IgG	
Gebrecherkos	Canea, Cellex, VivaChek, Innovita; ECLIA Roche	N+S IgG or IgM (Cenea, Cellex, VivaChek, Innovite), N all immunoglobulin (Roche)	
Mboumba Bouassa	BIOSYNEX, SIENNA, NG-test	RBD IgG and RBD IgM (BIOSYNEX), unknown antigen IgG and unknown antigen IgM (SIENNA), unknown antigen IgG and	

		unknown antigen IgM (NG-test)	
Gdoura	Vidas Biomerieux, Mindray, Elecsys Roche (Cobas), Access	S1 RBD IgG and S1 IgM (Vidas), S+N IgG and S+N IgG (Mindray), N all subclasses (Elecsys), S1 RBD IgG (Access)	
Vanroye	13 RDTs	N IgG or IgM (Toda, Biohit, Panbio, Boson), N+S IgG or IgM (Cellex, Dynamiker, Liming Bio), RBD IgG or IgM (ZenTech), N+RBD IgG or IgM (SureScreen Diagnostics, Singuway), N+RBD+S IgG or IgM (Multi-G), S IgG or IgM (Healgen), S (Wantai)	
Lapidus	ELISA	S1 IgG, S1 IgM	All participants have had malaria (different clinical phenotypes)

Naidoo	Elecsys Roche	N all subclasses, S all subclasses	
Li	Bead-based assay	S2 IgG	HIV, *Plasmodium* smear (no statistically significant differences); several others, but only in those samples with anti-S2 reactivity
Nantambi	In-house ELISA	N IgG, S IgG	HIV
Aissatou	Panbio IgG, IgM, IgG/IgM	N IgG, N IgM, N IgG/IgM	HIV

Table 3. Summary estimates of anti-SARS-CoV-2 cross-reactivity

SUBGROUPS	Datasets (samples)	Cross-reactivity (95% CI), %	I^2
Antigenic target[a]			
Any N	49 (8,650)	14 (11-16)	96.5%
Any S	81 (18,404)	11 (10-12)	97.0%
S1	26 (3,563)	23 (18-27)	98.1%
RBD	26 (7.032)	7 (5-8)	95.4%
Any N +S	24 (2,679)	5 (3-8)	92.2%
Type of antibodies[b]			
IgG	112 (23,164)	11 (9-12)	96.3%
IgM	18 (2,562)	13 (9-18)	96.3%
IgG/IgM	19 (3,128)	12 (9-16)	97.3%
Malaria burden[c]			
High	126 (25,019)	14 (12-15)	96.9%
Low/None	30 (4,004)	2 (1-2)	78.8%
Dengue burden[c]			
High	118 (22,363)	12 (10-13)	96.5%
Low/None	38 (7,560)	9 (7-10)	96.1%
HIV burden[c]			
High	52 (10,050)	6 (5-7)	94.0%
Low/None	91 (17,338)	13 (11-15)	96.7%

According to chi-square Q-test, the differences between subgroups are highly statistically significant ($p<0.001$) for type of antigenic target, malaria burden, and HIV burden, nominally statistically significant ($p<0.05$) for dengue burden, and not statistically significant ($p>0.05$) for

type of antibody. [a]"Any S" includes S (n=15), S1 (n=26), S2 (n=9), RBD (n=26), RBM (n=1),

NTD (n=4); "N+S" includes N+S (n=17), N+RBD (n=2), N+RBD+S (n=1), N+S2 (n=2),

RBD+N (n=2); for n=2 the antigen was unknown [b]not shown are IgA (n=1 dataset), all

immunoglobulin subclasses (n=5 datasets) and unclear (n=1 dataset)

[c]see Methods for definitions of subgroups.

Figure 1

2284 items retrieved through PubMed search

2237 items excluded upon title/abstract screening

47 potentially eligible studies
were screened in-depth

24 excluded upon further scrutiny (No usable African
       samples n=1, No pre-pandemic samples n=5, Pre-
498   pandemic samples cannot be separated n=3,
       Calibration of new assay specificity n=9, Assays
499   previously calibrated in African samples n=2, Excluded
       pre-pandemic samples positive by other assays n=1,
500   Pre-pandemic samples used as controls for peptide
501   array analysis n=1, Data included in other study n=2)

502   23 eligible studies

506   3 additional study retrieved in cited literature
       and citations (Diagne, Li, Naidoo)

510   26 eligible studies